1. Home
  2. GERN vs TPB Comparison

GERN vs TPB Comparison

Compare GERN & TPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.10

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Turning Point Brands Inc.

TPB

Turning Point Brands Inc.

HOLD

Current Price

$64.06

Market Cap

1.2B

ML Signal

HOLD

Company Overview

Basic Information
Metric
GERN
TPB
Founded
1990
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Tobacco
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.2B
IPO Year
1996
2015

Fundamental Metrics

Financial Performance
Metric
GERN
TPB
Price
$1.10
$64.06
Analyst Decision
Buy
Strong Buy
Analyst Count
5
6
Target Price
$4.25
★ $118.50
AVG Volume (30 Days)
★ 5.9M
408.8K
Earning Date
11-04-2026
11-04-2026
Dividend Yield
N/A
★ 0.48%
EPS Growth
★ 51.85
45.33
EPS
N/A
★ 3.11
Revenue
$1,065,000.00
★ $463,062,000.00
Revenue This Year
$28.49
$22.45
Revenue Next Year
$44.73
$12.73
P/E Ratio
★ N/A
$21.51
Revenue Growth
N/A
★ 28.39
52 Week Low
$1.04
$54.17
52 Week High
$2.01
$146.90

Technical Indicators

Market Signals
Indicator
GERN
TPB
Relative Strength Index (RSI) 32.01 52.96
Support Level $1.08 $54.43
Resistance Level $1.26 $91.03
Average True Range (ATR) 0.05 2.63
MACD -0.00 1.66
Stochastic Oscillator 8.33 68.21

Price Performance

Historical Comparison
GERN
TPB

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

About TPB Turning Point Brands Inc.

Turning Point Brands Inc operates as a manufacturer, marketer, and provider of consumer products that include Other Tobacco Products (OTP) in the U.S. The company offers a wide variety across the OTP spectrum, including moist snuff tobacco (MST), loose-leaf chewing tobacco, premium cigarette papers, make- your-own (MYO) cigar wraps, cigars, liquid vapor products, and tobacco vaporizer products. It operates in two segments, namely Zig-Zag products and Stoker's products segment. The company generates maximum revenue from the Zig-Zag products segment.

Share on Social Networks: